2018;264:58-63. 97. Kuo L, Chao TF, Liu CJ, et al. Liver cirrhosis in patients with atrial brillation: would oral anticoagulation have a net clinical bene t for stroke prevention? J Am Heart Assoc. 2017;6(6). 98. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial brillation: the Euro Heart Survey. Chest. 2010;138(5):1093-1100. 99. Gage BF, Yan Y, Milligan PE, et al. Clinical classi cation schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;151(3):713-719. 100. Hijazi Z, Oldgren J, Lindback J, et al. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial brillation: a derivation and validation study. Lancet. 2016;387(10035):2302-2311. 101. O Brien EC, Simon DN, Thomas LE, et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial brillation. Eur Heart J. 2015;36(46):3258-3264. 102. Shireman TI, Mahnken JD, Howard PA, Kresowik TF, Hou Q, Ellerbeck EF. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest. 2006;130(5):1390-1396. 103. Zulki y HH, Lip GYH, Lane DA. Bleeding risk scores in atrial brillation and venous thromboembolism. Am J Cardiol. 2017;120(7):1139-1145. 104. Apostolakis S, Lane DA, Buller H, Lip GY. Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial brillation: the AMADEUS trial. Thromb Haemost. 2013;110(5):1074-1079. 105. Roldan V, Marin F, Manzano-Fernandez S, et al. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial brillation. J Am Coll Cardiol. 2013;62(23):2199-2204. 106. 